High proportion of heteroresistance in gyra and gyrb in fluoroquinolone-resistant mycobacterium tuberculosis clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3270-3275

  Eilertson, Brandon ^a,b   Maruri, Fernanda ^a,b   Blackman, Amondrea ^a,b   Herrera, Miguel ^b   Samuels, David C ^b   Sterling, Timothy R ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; OFLOXACIN; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL DNA; DNA TOPOISOMERASE (ATP HYDROLYSING);

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SANGER SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG EFFECTS; GENETICS; LUNG TUBERCULOSIS; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; PHENOTYPE;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84901252315     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02066-13     Document Type: Article

References (27)

1. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J. Antimicrob. Chemother. 67:819-831. http://dx.doi.org/10. 1093/jac/dkr566.
2. Chen J, Chen Z, Li Y, Xia W, Chen X, Chen T, Zhou L, Xu B, Xu S. 2012. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. Braz. J. Infect. Dis. 16:136-141. http://dx.doi.org/10.1016/S1413-8670(12)70294-5.
3. Chernyaeva E, Fedorova E, Zhemkova G, Korneev Y, Kozlov A. 2013. Characterization of multiple and extensively drug resistant Mycobacterium tuberculosis isolates with different ofloxacin-resistance levels. Tuberculosis (Edinb.) 93:291-295. http://dx.doi.org/10.1016/j.tube.2013.02.005.
4. Jnawali HN, Hwang SC, Park YK, Kim H, Lee YS, Chung GT, Choe KH, Ryoo S. 2013. Characterization of mutations in multi-And extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea. Diagn. Microbiol. Infect. Dis. 76:187-196. http://dx.doi.org/10.1016/j. diagmicrobio.2013.02.035.
5. Köser CU, Feuerriegel S, Summers DK, Archer JA, Niemann S. 2012. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob. Agents Chemother. 56:6080-6087. http://dx.doi.org/10. 1128/AAC.01641-12.
6. Hofmann-Thiel S, van Ingen J, Feldmann K, Turaev L, Uzakova GT, Murmusaeva G, van Soolingen D, Hoffmann H. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur. Respir. J. 33:368-374. http://dx.doi.org/10.1183/09031936.00089808.
7. Rohlin A, Wernersson J, Engwall Y, Wiklund L, Bjork J, Nordling M. 2009. Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques. Hum. Mutat. 30: 1012-1020. http://dx.doi.org/10.1002/humu.20980.
8. Rinder H, Mieskes KT, Löscher T. 2001. Heteroresistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 5:339-345.
9. Sun G, Luo T, Yang C, Dong X, Li J, Zhu Y, Zheng H, Tian W, Wang S, Barry CE, Mei J, Gao Q. 2012. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J. Infect. Dis. 206:1724-1733. http://dx.doi.org/10.1093/infdis/jis601.
10. Ford C, Yusim K, Ioerger T, Feng S, Chase M, Greene M, Korber B, Fortune S. 2012. Mycobacterium tuberculosis-heterogeneity revealed through whole genome sequencing. Tuberculosis (Edinb.) 92:194-201. http://dx.doi.org/10.1016/j.tube. 2011.11.003.
11. Martín A, Herranz M, Navarro Y, Lasarte S, Ruiz Serrano MJ, Bouza E, Garcia de Viedma D. 2011. Evaluation of the inaccurate assignment of mixed infections by Mycobacterium tuberculosis as exogenous reinfection and analysis of the potential role of bacterial factors in reinfection. J. Clin. Microbiol. 49:1331-1338. http://dx.doi.org/10.1128/JCM.02519-10.
12. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, Smith T, Hooper N, Maruri F, Warkentin J, Mitchel E, Sterling TR. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am. J. Respir. Crit. Care Med. 180:365-370. http://dx.doi.org/10.1164/rccm.200901-0146OC.
13. Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A, Alexander C, Kaiga A, Stratton CW, Warkentin J, Tang YW, Sterling TR. 2012. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J. Clin. Microbiol. 50:1390-1396. http://dx.doi.org/10.1128/JCM. 05286-11.
14. CLSI. 2011. Susceptibility testing of mycobacteria, nocardiae and other aerobic actinomycetes; approved standard-2nd ed. M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Mazars E, Lesjean S, Banuls AL, Gilbert M, Vincent V, Gicquel B, Tibayrenc M, Locht C, Supply P. 2001. High-resolution minisatellitebased typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology. Proc. Natl. Acad. Sci. U. S. A. 98: 1901-1906. http://dx.doi.org/10.1073/pnas.98.4.1901.
16. Ghosh S, Moonan PK, Cowan L, Grant J, Kammerer S, Navin TR. 2012. Tuberculosis genotyping information management system: enhancing tuberculosis surveillance in the United States. Infect. Genet. Evol. 12:782-788. http://dx.doi.org/10.1016/j.meegid.2011.10.013.
17. Joshi NA, Fass JN. 2011. Sickle: a sliding-window, adaptive, quality-based trimming tool for FastQ files. https://github.com/najoshi/sickle.
18. Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26:589-595. http://dx.doi.org/10.1093/ bioinformatics/btp698.
19. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25:2078-2079. http://dx.doi.org/10.1093/bioinformatics/btp352.
20. Cingolani P, Platts A, Wang LE, Coon LM, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. 2012. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6:80-92. http://dx.doi.org/10.4161/fly. 19695.
21. Liu Q, Guo Y, Li J, Long J, Zhang B, Shyr Y. 2012. Steps to ensure accuracy in genotype and SNP calling from Illumina sequencing data. BMC Genomics 13(Suppl 8):S8. http://dx.doi.org/10.1186/1471-2164-13-S8-S8.
22. Streicher EM, Bergval I, Dheda K, Bottger EC, Gey van Pittius NC, Bosman M, Coetzee G, Anthony RM, van Helden PD, Victor TC, Warren RM. 2012. Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. Antimicrob. Agents Chemother. 56:2420-2427. http://dx.doi.org/10.1128/AAC.05905-11.
23. Zhang X, Zhao B, Liu L, Zhu Y, Zhao Y, Jin Q. 2012. Subpopulation analysis of heteroresistance to fluoroquinolone in Mycobacterium tuberculosis isolates from Beijing, China. J. Clin. Microbiol. 50:1471-1474. http://dx.doi.org/10.1128/JCM.05793-11.
24. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, Chakravorty S, Jones M, Alland D. 2010. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J. Clin. Microbiol. 48:2495-2501. http://dx.doi.org/10.1128/JCM. 00128-10.
25. Rozen DE, McGee L, Levin BR, Klugman KP. 2007. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:412-416. http://dx.doi.org/10.1128/AAC.01161-06.
26. Han J, Wang Y, Sahin O, Shen Z, Guo B, Shen J, Zhang Q. 2012. A fluoroquinolone resistance associated mutation in gyrA affects DNA supercoiling in Campylobacter jejuni. Front. Cell Infect. Microbiol. 2:21. http://dx.doi.org/10.3389/fcimb.2012.00021.
27. Kunz AN, Begum AA, Wu H, D'Ambrozio JA, Robinson JM, Shafer WM, Bash MC, Jerse AE. 2012. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J. Infect. Dis. 205:1821-1829. http://dx.doi.org/10.1093/infdis/jis277.